A New Drug Application for the investigational oral selective estrogen receptor degrader giredestrant has received Priority ...

A phase 2 trial is investigating MTX-001, an injectable regenerative therapy, for patients with noninfected venous leg ulcers.

Increased T-cell receptor clonality and novel clonotypes seen with intismeran plus pembrolizumab versus pembrolizumab alone.

Zaynich is a combination of cefepime, a cephalosporin antibacterial, and zidebactam, a beta-lactamase inhibitor and non-beta-lactam antibacterial.

A total of 10,225 patients with stage I to III cancer who initiated GLP-1 RA therapy after diagnosis were identified for the trial. HealthDay News — Across multiple solid tumors, glucagon-like peptide ...

While California has some of the strictest vaccine laws in the country, conservative Shasta County’s approach during the COVID pandemic stood in stark contrast with the state’s guidance.

The court cited threats to Kenyan lives and barred entrance to the country to anyone from Ebola-affected regions ...

The combination regimen significantly improved progression-free survival and objective response rates in patients who were intolerant to or failed prior imatinib therapy ...

The 3-month extension follows a major amendment to the NDA for the intrathecal cyclodextrin-based therapy, which has shown a 71% reduction in mortality risk in clinical trials.

Backed by the phase 2b/3 EPICS-III trial, saroglitazar demonstrated a significant 56.7% biochemical response rate compared with 9.8% for placebo, while showing favorable safety data.

Tirzepatide is superior to intensified conventional care (ICC) for adults with early type 2 diabetes (T2D) uncontrolled with metformin, according to a study pub ...

Investigational oral substrate therapy BBP-418 demonstrated significant increases in alpha-dystroglycan glycosylation and improved ambulatory function in the phase 3 FORTIFY interim analysis.